Eli Lilly (LLY) to Invest $3 Billion in China Over the Next Decade, Reuters Reports

Eli Lilly and Company (NYSE:LLY) is one of the most profitable blue chip stocks to invest in now. Reuters reported on March 11 that Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China over the next decade, helping develop production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron. In a statement delivered on WeChat, the company stated that it submitted a marketing application for orforglipron ​to China’s drug regulator at the end of ​2025. It also plans to establish a localised manufacturing and supply ‌system ⁠for oral solid dosage forms, according to the statement.

RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market

Reuters provided additional context, stating that Eli Lilly and Company (NYSE:LLY) is the latest Western healthcare firm to announce additional manufacturing investment plans in China, following others, such as Haleon, earlier this year. However, not all drugmakers are following this path, as Bristol Myers Squibb announced on September the signing of an agreement to sell its 60% ownership stake in a ⁠pharmaceutical ​joint venture in China, with a manufacturing ​facility in Shanghai part of the venture.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.